JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study

  • 0Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Therapeutic Advances in Medical Oncology +

|

June 19, 2025

|

June 19, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Human epidermal factor receptor 2 (HER2)-positive microinvasive breast cancer shows a good prognosis, with chemotherapy or targeted therapy offering limited benefit. Younger patients (age ≤40) may have a poorer outlook, warranting further investigation.

Area Of Science

  • Oncology
  • Breast Cancer Research
  • Clinical Oncology

Background

  • Limited evidence exists regarding the prognosis of human epidermal factor receptor 2 (HER2)-positive microinvasive breast cancer (MIBC).
  • The efficacy of chemotherapy (CT) and targeted therapy in HER2-positive MIBC remains unclear.

Purpose Of The Study

  • To investigate the prognosis of HER2-positive MIBC.
  • To evaluate the effectiveness of treatment strategies, including chemotherapy and targeted therapy, for HER2-positive MIBC.

Main Methods

  • A retrospective, multicenter, real-world study.
  • Inclusion of 163 patients with lymph node-negative HER2-positive MIBC diagnosed between January 2010 and December 2020.
  • Propensity score matching was used to compare treatment outcomes.

Main Results

  • The overall 3-year and 5-year disease-free survival (DFS) rates were 95.1%.
  • Patients aged 40 years or younger experienced significantly worse outcomes compared to older patients (3-year DFS 81.8% vs. 96.1%, p=0.046).
  • Adjuvant chemotherapy or targeted therapy (including trastuzumab) did not demonstrate a significant improvement in DFS rates compared to no treatment (3-year DFS 95.0% vs. 95.0%, p=0.630).

Conclusions

  • HER2-positive MIBC generally has a favorable prognosis.
  • Age ≤40 years may indicate a poorer prognostic factor in HER2-positive MIBC.
  • Current chemotherapy and targeted therapy regimens appear to offer minimal additional benefit for MIBC patients, necessitating further research, particularly for younger individuals.

Keywords: